Stinson et al found that fasting levels of both GLP-1 and glucagon were elevated in the group with obesity and insulin resistance compared to the group with normal weight
Phase 3 trials (the TRIUMPH programme) are underway
The use of GLP-1 medications has increased significantly in recent years, representing one of the fastest-growing pharmaceutical categories in the United States
Current access: Clinical trials at major research hospitals, compounding pharmacies (varies by country
Just like stopping insulin or blood-pressure tablets, weight can return if you dont have a long-term plan- healthy food, strength training, and sometimes maintenance doses or lifestyle support
RESULTS Among 106,088 individuals in the cohort, most were male ( n = 44,059, 51.3%), and mean age was 51 (SD: 9.8) years